Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
https://www.bloomberg.com/news/articles/2025-11-12/lilly-drops-cvs-drug-plan-for-workers-after-novo-obesity-deal
A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...
Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to hi...
Freedom Capital Markets analyst Ilya Zubkov downgrades Eli Lilly (NYSE:LLY) from Buy to Hold and raises the price target fro...
Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.
Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown i...
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children w...
